Detalles de la búsqueda
1.
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Lancet Oncol
; 25(4): 474-487, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38547892
2.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood
; 129(19): 2612-2615, 2017 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28373262
3.
Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.
Br J Haematol
; 185(1): 148-150, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29855051
4.
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Lancet Oncol
; 14(3): 228-35, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23414585
5.
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Clin Lymphoma Myeloma Leuk
; 18(12): 803-813.e7, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30249389
6.
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
Clin Cancer Res
; 19(15): 4282-9, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23741071
Resultados
1 -
6
de 6
1
Próxima >
>>